Immunotherapy plus local treatments for early spread lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding local treatments like radiation or surgery to standard immunotherapy can help people with lung cancer that has spread to a few spots. It aims to see if this combination improves control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer that has spread to a small number of spots (up to 5) in no more than 3 organs.
- You are eligible to receive standard immunotherapy as your first treatment.
- Your tumors that have spread can be treated with local radiation or surgery, and each is 5 cm or smaller on a CT scan.
- You are in fairly good health (ECOG performance status 0 or 1).
- You are 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares continuing drug therapy alone versus adding local treatments (surgery or radiation) for people with stage IV lung cancer that has responded to initial treatment but still has a few remaining spots (oligometastatic). The goal is to see if targeting those spots with local therapy helps control the cancer longer.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy (and sometimes radiation) for people with small cell lung cancer that has spread to only a few spots in the body. The goal is to see if adding immunotherapy helps control the cancer better than chemotherapy alone.
This trial compares two approaches after initial chemotherapy and immunotherapy for advanced non-small cell lung cancer: giving additional local treatment (like surgery or radiation) to remaining spots versus continuing immunotherapy. It aims to see which strategy better controls the cancer.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial explores whether combining radiation therapy with immunotherapy can trigger an immune response that shrinks tumors throughout the body (abscopal effect) in people with non-small cell lung cancer that has spread to 3 to 6 other sites. It tests different patterns of these treatments to see which works best.
This trial tests whether giving radiotherapy to the main lung tumor, along with the usual medicines (like chemotherapy or immunotherapy), can help people with stage IV lung cancer. The goal is to see if adding this treatment helps control the cancer and improves how long patients live.
Hear when a new Oligometastatic Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.